Top

BMC Neurology

Published in:

Open Access 01-12-2016 | Research article

Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review

Author: Ovais Shafi

Published in: BMC Neurology | Issue 1/2016

Abstract

Background

The AD etiology is yet not properly known. Interactions among environmental factors, multiple susceptibility genes and aging, contribute to AD. This study investigates the factors that play role in causing AD and how changes in cellular pathways contribute to AD.

Methods

PUBMED database, MEDLINE database and Google Scholar were searched with no date restrictions for published articles involving cellular pathways with roles in cancers, cell survival, growth, proliferation, development, aging, and also contributing to Alzheimer’s disease. This research explores inverse relationship between AD and cancer, also investigates other factors behind AD using several already published research literature to find the etiology of AD.

Results

Cancer and Alzheimer’s disease have inverse relationship in many aspects such as P53, estrogen, neurotrophins and growth factors, growth and proliferation, cAMP, EGFR, Bcl-2, apoptosis pathways, IGF-1, HSV, TDP-43, APOE variants, notch signals and presenilins, NCAM, TNF alpha, PI3K/AKT/MTOR pathway, telomerase, ROS, ACE levels. AD occurs when brain neurons have weakened growth, cell survival responses, maintenance mechanisms, weakened anti-stress responses such as Vimentin, Carbonic anhydrases, HSPs, SAPK. In cancer, these responses are upregulated and maintained. Evolutionarily conserved responses and maintenance mechanisms such as FOXO are impaired in AD.

Countermeasures or compensatory mechanisms by AD affected neurons such as Tau, Beta Amyloid, S100, are last attempts for survival which may be protective for certain time, or can speed up AD in Alzheimer’s microenvironment via C-ABL activation, GSK3, neuro-inflammation.

Conclusions

Alzheimer’s disease and Cancer have inverse relationship; many factors that are upregulated in any cancer to sustain growth and survival are downregulated in Alzheimer’s disease contributing to neuro-degeneration. When aged neurons or genetically susceptible neurons have weakened growth, cell survival and anti-stress responses, age related gene expression changes, altered regulation of cell death and maintenance mechanisms, they contribute to Alzheimer’s disease. Countermeasures by AD neurons such as Beta Amyloid Plaques, NFTs, S100, are last attempts for survival and this provides neuroprotection for certain time and ultimately may become pathological and speed up AD. This study may contribute in developing new potential diagnostic tests, interventions and treatments.

Available only for authorised users

Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C, Palmer K, Russo A. Inverse occurrence of cancer and Alzheimer disease. Neurology. 2013;81(4):322–8. doi:10.1212/WNL.0b013e31829c5ec1.CrossRefPubMed

Realmuto S, Cinturino A, Arnao V, Mazzola MA, Cupidi C, Aridon P, Ragonese P, Savettieri G, D’Amelio M. Tumor diagnosis preceding Alzheimer’s disease onset: is there a link between cancer and Alzheimer’s disease? J Alzheimers Dis. 2012;31(1):177–82. doi:10.3233/JAD-2012-120184.PubMed

Sørensen SA, Fenger K, Olsen JH. Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer. 1999;86(7):1342–6.CrossRefPubMed

Dulić V, Beney G-E, Frebourg G, Drullinger LF, Stein GH. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. Mol Cell Biol. 2000;20(18):6741–54.CrossRefPubMedPubMedCentral

Proctor CJ, Gray DA. GSK3 and p53 - is there a link in Alzheimer’s disease? Mol Neurodegener. 2010;5:7. doi:10.1186/1750-1326-5-7.CrossRefPubMedPubMedCentral

Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475–84. doi:10.1177/1947601911413466.CrossRefPubMedPubMedCentral

Yamamori H, Tanaka T, Kudo T, Takeda M. Amyloid-beta down-regulates XIAP expression in human SH-SY5Y neuroblastoma cells. Neuroreport. 2004;15(5):851–4.CrossRefPubMed

Shepherd JE. Effects of estrogen on congnition mood, and degenerative brain diseases. J Am Pharm Assoc (Wash). 2001;41(2):221–8.CrossRef

Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11(6):635–40.CrossRefPubMed

10.

Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer. 2010;9:157. doi:10.1186/1476-4598-9-157.CrossRefPubMedPubMedCentral

11.

Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144:97–112. doi:10.1196/annals.1418.005.CrossRefPubMedPubMedCentral

12.

Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. doi:10.1146/annurev.neuro.24.1.677.

13.

Montano X, Djamgoz MB. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett. 2004;571(1-3):1–8.CrossRefPubMed

14.

Yang X, Martin TA, Jiang WG. Biological influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells. Exp Ther Med. 2013;6(6):1475–81. doi:10.3892/etm.2013.1330. Epub 2013 Oct 7. PMCID: PMC3829751.PubMedPubMedCentral

15.

Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT, Ingelsson M. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol. 2005;194(1):91–6. doi:10.1016/j.expneurol.2005.01.026.CrossRefPubMed

16.

Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017–22. doi:10.1073/pnas.1015950108. Epub 2011 Jan 31.CrossRefPubMedPubMedCentral

17.

Catoire M, Mensink M, Boekschoten MV, Hangelbroek R, Müller M, Schrauwen P, Kersten S. Pronounced effects of acute endurance exercise on gene expression in resting and exercising human skeletal muscle. PLoS One. 2012;7(11):e51066. doi:10.1371/journal.pone.0051066. Epub 2012 Nov 30.CrossRefPubMedPubMedCentral

18.

Rönn T, Volkov P, Davegårdh C, Dayeh T, Hall E, Olsson AH, et al. A Six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 2013;9(6):e1003572. doi:10.1371/journal.pgen.1003572.CrossRefPubMedPubMedCentral

19.

Nam SM, Kim JW, Yoo DY, Yim HS, Kim DW, Choi JH, Kim W, Jung HY, Won MH, Hwang IK, Seong JK, Yoon YS. Physical exercise ameliorates the reduction of neural stem cell, cell proliferation and neuroblast differentiation in senescent mice induced by D-galactose. BMC Neurosci. 2014;15:116. doi:10.1186/s12868-014-0116-4.CrossRefPubMedPubMedCentral

20.

Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8. doi:10.1056/NEJM200005043421807.CrossRefPubMed

21.

Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):930–41. doi:10.1016/j.biopsych.2010.06.012. Epub 2010 Aug 8.CrossRefPubMed

22.

Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM, Gutmann DH. Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem. 1999;274(36):25842–8.CrossRefPubMed

23.

Hanson Jr MG, Shen S, Wiemelt AP, McMorris FA, Barres BA. Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J Neurosci. 1998;18(18):7361–71.PubMed

24.

Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, Rechavi G, Galun E, Honigman A. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 2004;64(4):1338–46. doi:10.1158/0008-5472.CAN-03-2089.CrossRefPubMed

25.

Bodey B, Kaiser HE, Siegel SE. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors. In Vivo. 2005;19(5):931–41. PMID: 16097449.PubMed

26.

Birecree E, Whetsell Jr WO, Stoscheck C, King Jr LE, Nanney LB. Immunoreactive epidermal growth factor receptors in neuritic plaques from patients with Alzheimer’s disease. J Neuropathol Exp Neurol. 1988;47(5):549–60.CrossRefPubMed

27.

Sun D, Bullock MR, Altememi N, Zhou Z, Hagood S, Rolfe A, McGinn MJ, Hamm R, Colello RJ. The effect of epidermal growth factor in the injured brain after trauma in rats. J Neurotrauma. 2010;27(5):923–38. doi:10.1089/neu.2009.1209.CrossRefPubMedPubMedCentral

28.

Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid beta peptide of Alzheimer’s disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci. 1996;16(23):7533–9.PubMed

29.

Song YS, Park HJ, Kim SY, Lee SH, Yoo HS, Lee HS, Lee MK, Oh KW, Kang SK, Lee SE, Hong JT. Protective role of Bcl-2 on beta-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-kappaB and p38 MAP kinase activation. Neurosci Res. 2004;49(1):69–80.CrossRefPubMed

30.

Weroha SJ, Haluska P. IGF system in cancer. Endocrinol Metab Clin N Am. 2012;41(2):335–50. doi:10.1016/j.ecl.2012.04.014.CrossRef

31.

Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta. 2010;1802(1):2–10. doi:10.1016/j.bbadis.2009.10.006. Epub 2009 Oct 21.CrossRefPubMed

32.

Westwood AJ, Beiser A, Decarli C, Harris TB, Chen TC, He XM, Roubenoff R, Pikula A, Au R, Braverman LE, Wolf PA, Vasan RS, Seshadri S. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014;82(18):1613–9. doi:10.1212/WNL.0000000000000382. Epub 2014 Apr 4.CrossRefPubMedPubMedCentral

33.

Biessels GJ, Kappelle LJ, Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33(Pt 5):1041–4. doi:10.1042/BST20051041.CrossRefPubMed

34.

Ojaimi J, Masters CL, McLean C, Opeskin K, McKelvie P, Byrne E. Irregular distribution of cytochrome c oxidase protein subunits in aging and Alzheimer’s disease. Ann Neurol. 1999;46(4):656–60.CrossRefPubMed

35.

Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener. 2011;6:85. doi:10.1186/1750-1326-6-85.CrossRefPubMedPubMedCentral

36.

Martinez-Canabal A. Reconsidering hippocampal neurogenesis in Alzheimer’s disease. Front Neurosci. 2014;8:147. doi:10.3389/fnins.2014.00147. Published online 2014 Jun 11.CrossRefPubMedPubMedCentral

37.

Kohman RA, Rhodes JS. Neurogenesis, inflammation and behavior. Brain Behav Immun. 2013;27(1):22–32. doi:10.1016/j.bbi.2012.09.003. Epub 2012 Sep 15.CrossRefPubMed

38.

Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia. 1999;1(5):387–401.CrossRefPubMedPubMedCentral

39.

Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol. 2009;217(1):131–8. doi:10.1002/path.2449.CrossRefPubMed

40.

Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007;429(2-3):95–100. Epub 2007 Oct 13.CrossRefPubMed

41.

Wilson AC, Dugger BN, Dickson DW, Wang D-S. TDP-43 in aging and Alzheimer’s disease - a review. Int J Clin Exp Pathol. 2011;4(2):147–55. PMCID: PMC3037200.PubMedPubMedCentral

42.

Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A. 2008;105(10):3785–9. doi:10.1073/pnas.0800546105. Epub 2008 Feb 27.CrossRefPubMedPubMedCentral

43.

Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Jack Jr CR, Parisi JE, Petersen RC, Dickson DW. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol. 2014;127(6):811–24. doi:10.1007/s00401-014-1269-z. Epub 2014 Mar 23.CrossRefPubMedPubMedCentral

44.

Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20(10):1952–65. doi:10.1093/hmg/ddr076. Epub 2011 Feb 25.CrossRefPubMedPubMedCentral

45.

Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol. 2013;9(2):106–18. doi:10.1038/nrneurol.2012.263.CrossRefPubMedPubMedCentral

46.

Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180–4.CrossRefPubMed

47.

Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30.CrossRefPubMed

48.

Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IM. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 2005;65(1):331–7.PubMed

49.

Yang CP, Gilley JA, Zhang G, Kernie SG. ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development. 2011;138(20):4351–62. doi:10.1242/dev.065540. Epub 2011 Aug 31.CrossRefPubMedPubMedCentral

50.

Niemi M, Hakkinen T, Karttunen TJ, Eskelinen S, Kervinen K, Savolainen MJ, Lehtola J, Makela J, Yla-Herttuala S, Kesaniemi YA. Apolipoprotein E and colon cancer. Expression in normal and malignant human intestine and effect on cultured human colonic adenocarcinoma cells. Eur J Intern Med. 2002;13(1):37–43.CrossRefPubMed

51.

Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994;54(3):299–308.CrossRefPubMed

52.

Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, et al. Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use. PLoS One. 2013;8(2):e54713. doi:10.1371/journal.pone.0054713.CrossRefPubMedPubMedCentral

53.

Raber J. AR, apoE, and cognitive function. Horm Behav. 2008;53(5):706–15. doi:10.1016/j.yhbeh.2008.02.012. Epub 2008 Feb 26.CrossRefPubMedPubMedCentral

54.

Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. Semin Cancer Biol. 2004;14(5):320–8. doi:10.1016/j.semcancer.2004.04.011.CrossRefPubMed

55.

Thinakaran G. The role of presenilins in Alzheimer’s disease. Clin Invest. 1999;104(10):1321–7. doi:10.1172/JCI8728.CrossRef

56.

Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1(5):466–76.CrossRefPubMed

57.

Aisa B, Gil-Bea FJ, Solas M, García-Alloza M, Chen CP, Lai MK, Francis PT, Ramírez MJ. Altered NCAM expression associated with the cholinergic system in Alzheimer’s disease. J Alzheimers Dis. 2010;20(2):659–68. doi:10.3233/JAD-2010-1398. PMID: 20164549.PubMed

58.

Leshchyns’ka I, Liew HT, Shepherd C, Halliday GM, Stevens CH, Ke YD, Ittner LM, Sytnyk V. Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer’s disease. Nat Commun. 2015;6:8836. doi:10.1038/ncomms9836.CrossRefPubMedPubMedCentral

59.

Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal. 2010;22(7):977–83. doi:10.1016/j.cellsig.2010.01.010.CrossRefPubMedPubMedCentral

60.

Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S. Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease. Alzheimers Res Ther. 2014;6(3):35. doi:10.1186/alzrt265. PMCID: PMC4075129.CrossRefPubMedPubMedCentral

61.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64. doi:10.3389/fonc.2014.00064.CrossRefPubMedPubMedCentral

62.

Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011;21(6):349–53. doi:10.1016/j.semcancer.2011.10.001.CrossRefPubMedPubMedCentral

63.

Avramopoulos D, Szymanski M, Wang R, Bassett S. Gene expression reveals overlap between normal aging and Alzheimer’s disease genes. Neurobiol Aging. 2011;32(12):2319. doi:10.1016/j.neurobiolaging.2010.04.019. e27-34.CrossRefPubMed

64.

Lee J, Ryu H. Epigenetic modification is linked to Alzheimer’s disease: is it a maker or a marker? BMB Rep. 2010;43(10):649–55. doi:10.5483/BMBRep.2010.43.10.649.CrossRefPubMed

65.

Daniilidou M, Koutroumani M, Tsolaki M. Epigenetic mechanisms in Alzheimer’s disease. Curr Med Chem. 2011;18(12):1751–6.CrossRefPubMed

66.

Domazet-Lošo T, Klimovich A, Anokhin B, Anton-Erxleben F, Hamm MJ, Lange C, Bosch TC. Naturally occurring tumours in the basal metazoan Hydra. Nat Commun. 2014;5:4222. doi:10.1038/ncomms5222.PubMed

67.

Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer’s disease? Neurobiol Aging. 1995;16(4):661–74.CrossRefPubMed

68.

Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10(3):175–6. http://dx.doi.org/10.1016/j.ccr.2006.08.015.CrossRefPubMed

69.

Mansfield CM, Kimler BF, Henderson SD, Vats TS, Svoboda DJ. Angiotensin-I-converting enzyme in cancer patients. J Clin Oncol. 1984;2(5):452–6. PMID: 6327925.PubMed

70.

Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34(2):181–93. doi:10.1111/j.1365-2990.2007.00885.x. Epub 2007 Oct 31.CrossRefPubMed

71.

Yamada T, Kawamata T, Walker DG, McGeer PL. Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol. 1992;84(2):157–62.CrossRefPubMed

72.

Levin EC, Acharya NK, Sedeyn JC, Venkataraman V, D’Andrea MR, Wang HY, Nagele RG. Neuronal expression of vimentin in the Alzheimer’s disease brain may be part of a generalized dendritic damage-response mechanism. Brain Res. 2009;1298:194–207. doi:10.1016/j.brainres.2009.08.072. Epub 2009 Sep 1.CrossRefPubMed

73.

Satelli A, Li S. Vimentin as a potential molecular target in cancer therapy Or Vimentin, an overview and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–46. doi:10.1007/s00018-011-0735-1.CrossRefPubMedPubMedCentral

74.

Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–46. doi:10.1007/s00018-011-0735-1. Epub 2011 Jun 3.CrossRefPubMedPubMedCentral

75.

Hipkiss AR. Could carnosine or related structures suppress Alzheimer’s disease? J Alzheimers Dis. 2007;11(2):229–40. PMID: 17522447.PubMed

76.

Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des. 2008;14(7):685–98.CrossRefPubMed

77.

Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, Hengstler J, Gebhardt R, Meixensberger J, Gaunitz F. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer. 2010;9:2. doi:10.1186/1476-4598-9-2.CrossRefPubMedPubMedCentral

78.

Zhang Z, Miao L, Wu X, et al. Carnosine inhibits the proliferation of human gastric carcinoma cells by retarding Akt/mTOR/p70S6K signaling. J Cancer. 2014;5(5):382–9. doi:10.7150/jca.8024.CrossRefPubMedPubMedCentral

79.

Hipkiss AR. On the enigma of carnosine’s anti-ageing actions. Exp Gerontol. 2009;44(4):237–42. doi:10.1016/j.exger.2008.11.001. Epub 2008 Nov 11.CrossRefPubMed

80.

Diller KR. Stress protein expression kinetics. Annu Rev Biomed Eng. 2006;8:403–24.CrossRefPubMed

81.

Salamanca HH, Antonyak MA, Cerione RA, Shi H, Lis JT. Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamer. PLoS One. 2014;9(5):e96330. doi:10.1371/journal.pone.0096330.CrossRefPubMedPubMedCentral

82.

Hammond-Martel I, Yu H, el Affar B. Roles of ubiquitin signaling in transcription regulation. Cell Signal. 2012;24(2):410–21. doi:10.1016/j.cellsig.2011.10.009. Epub 2011 Oct 17.CrossRefPubMed

83.

Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML, Oberhauser AF, Barral JM, Boehning D. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem. 2011;286(41):35689–98. doi:10.1074/jbc.M111.243147. Epub 2011 Aug 18.CrossRefPubMedPubMedCentral

84.

Meller R, Thompson SJ, Lusardi TA, et al. Ubiquitin-proteasome mediated synaptic reorganization - a novel mechanism underlying rapid ischemic tolerance. J Neurosci. 2008;28(1):50–9. doi:10.1523/JNEUROSCI.3474-07.2008.CrossRefPubMedPubMedCentral

85.

Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002;3(5):420–5.CrossRefPubMedPubMedCentral

86.

Joshi YB, Praticò D. Vitamin E in aging, dementia, and Alzheimer’s disease. Biofactors. 2012;38(2):90–7. doi:10.1002/biof.195. Epub 2012 Mar 16.CrossRefPubMed

87.

Van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007;8(6):440–50.CrossRefPubMed

88.

Kim YT, Hur E-M, Snider WD, Zhou F-Q. Role of GSK3 signaling in neuronal morphogenesis. Front Mol Neurosci. 2011;4:48. doi:10.3389/fnmol.2011.00048.PubMedPubMedCentral

89.

Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11(8):539–51. doi:10.1038/nrn2870.CrossRefPubMedPubMedCentral

90.

Schlatterer SD, Tremblay MA, Acker CM, Davies P. Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis. 2011;25(1):119–33. doi:10.3233/JAD-2011-102025.PubMedPubMedCentral

91.

Wilcock DM, Griffin WS. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation. 2013;10:84. doi:10.1186/1742-2094-10-84.CrossRefPubMedPubMedCentral

92.

Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE axis in Alzheimer’s disease. Cardiovasc Psychiatry Neurol. 2010;2010:539581. doi:10.1155/2010/539581.CrossRefPubMedPubMedCentral

93.

Fuster-Matanzo A, Llorens-Martín M, Jurado-Arjona J, Avila J, Hernández F. Tau protein and adult hippocampal neurogenesis. Front Neurosci. 2012;6:104. doi:10.3389/fnins.2012.00104.CrossRefPubMedPubMedCentral

94.

Hong XP, Peng CX, Wei W, Tian Q, Liu YH, Yao XQ, Zhang Y, Cao FY, Wang Q, Wang JZ. Essential role of tau phosphorylation in adult hippocampal neurogenesis. Hippocampus. 2010;20(12):1339–49. doi:10.1002/hipo.20712.CrossRefPubMed

95.

Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M, Sunnemark D, von Euler G. MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies. Acta Neuropathol Commun. 2014;2:22. doi:10.1186/2051-5960-2-22.CrossRefPubMedPubMedCentral

96.

Osborne R. Myriad stumbles, Wyeth closes on Alzheimer’s. Nat Biotechnol. 2008;26(8):841–3. doi:10.1038/nbt0808-841.CrossRefPubMed

97.

Tucker RP. The roles of microtubule-associated proteins in brain morphogenesis: a review. Brain Res Brain Res Rev. 1990;15(2):101–20.CrossRefPubMed

98.

Hong XP, Peng CX, Wei W, Tian Q, Liu YH, Cao FY, Wang Q, Wang JZ. Relationship of adult neurogenesis with tau phosphorylation and GSK-3β activity in subventricular zone. Neurochem Res. 2011;36(2):288–96. doi:10.1007/s11064-010-0316-y.CrossRefPubMed

99.

Rosette C, Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J Cell Biol. 1995;128(6):1111–9.CrossRefPubMed

100.

Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M. Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem. 2003;278(45):44305–11. Epub 2003 Sep 1.CrossRefPubMed

101.

Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res. 2003;63(22):7891–9.PubMed

Title: Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review
Author: Ovais Shafi
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-016-0765-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Clapping-surpressed focal spikes in EEG may be unique for the patients with rett syndrome : a case report

Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study

Late-onset spinal form xanthomatosis without brain lesion: a case report

Intracranial extension of orbital inflammatory pseudotumor: a case report and literature review

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)

Ratio of apoB/LDL: a potential clinical index for vascular cognitive impairment